Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound

1 . A method for treating or preventing anemia or thrombocytopenia, comprising administering to a subject in need thereof an effective amount of a compound of Formula (Ia)

or a pharmaceutically acceptable salt thereof; wherein

Q 1 is —O—, —S— or —N(R 1 )—;

Q 2 is —C(R 3 )— or —N—;

Q 3 is —C(R 5 )— or —N—;

Q 4 is —C(R 9 )— or —N—;

R 1 is —Y m (R a ), wherein —R a is —H, —OH, —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —OS(O) 2 OH, —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , or —NR 14 C(S)N(R 14 ) 2 ;

R 2 is —H, —C 1 -C 8 alkyl or —OH;

R 3 , R 4 , and R 5 are independently —Y m (R b ), wherein R b is —H, halogen, —NH 2 , —CN, —NO 2 , —SH, —N 3 , —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n R 14 , —O(CH 2 ) n —C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSOR 14 , —NHS(O) 2 R 14 , O—C(S)R 14 , O—C(S)OR 14 , O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R, 4 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 or R 3 and R 4 , or R 4 and R 5 , together with the carbon atom to which each is attached, join to form a 5- to 9-membered ring, with the proviso that if Q 3 is —C(R 5 )— and m=0, then R 5 is not H;

R 6 is —H;

R 7 is —Y m —(R c ), wherein —R c is —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —O-benzyl, —OH, —NH 2 , —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —CN, —NO 2 , —N 3 , —C 2 -C 8 alkynyl, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O(CH 2 ) n C(O)O(CH 2 ) n CH 3 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 ;

R 8 is —Y m (R d ), wherein —R d is —H, —OH, halogen, —NH 2 , —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —CN, —NO 2 , —N 3 , —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —(C 1 -C 8 alkylene)-OH, —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 ;

R 9 , R 10 , R 11 , R 12 , and R 13 are independently —Y m (R e ), wherein —R e is —H, halogen, —NH 2 , C 1 -C 8 alkyl, —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(C 2 -C 5 alkenyl), —N(C 2 -C 5 alkenyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —C(O)NH(C 1 -C 5 alkyl), —C(O)N(C 1 -C 5 alkyl) 2 , —NHC(O)(C 1 -C 5 alkyl), —NHC(═NH 2 + )NH 2 , —CN, —NO 2 , N 3 , -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , C(O)C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 or R 11 and R 12 , together with the carbon atom to which each is attached, join to form a 5- to 9-membered ring;

each R 14 is independently —H, —C 1 -C 8 alkyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl; each Y is independently —C 1 -C 8 alkylene-, —C 2 -C 8 alkenylene- or —C 2 -C 8 alkynylene-;

each m is independently 0 or 1;

each n is independently an integer ranging from 0 to 6; and

each p is independently an integer ranging from 1 to 6.

2 . The method of claim 1 , further comprising administering another therapeutic agent.

3 . The method of claim 1 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

4 . A method for treating or preventing anemia or thrombocytopenia, comprising administering to a subject in need thereof an effective amount of a compound of Formula (Ib)

or a pharmaceutically acceptable salt thereof;

wherein

Q 1 is —O—, —S—or —N(R 1 )—;

Q 2 is —C(R 3 )— or —N—;

Q 3 is —C(R 5 )— or —N—;

Q 4 is —C(R 9 )— or —N—;

R 1 is —Y m (R a ), where R a is selected from —H, —OH, —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, —C 2 -C8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —OS(O) 2 OH, —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , or —NR 14 C(S)N(R 14 ) 2 ;

R 2 is —H, —C 3 -C 8 alkyl or —OH;

R 3 , R 4 , and R 5 are independently —Y m —(R b ), wherein R b is —H, halogen, —NH 2 , —CN, —NO 2 , —SH, —N 3 , —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —C(O)R 14 , —O(CH 2 ) n —C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 or R 3 and R 4 , or R 4 and R 5 together with the carbon atom to which each is attached, join to form a 5- to 9-membered ring, with the proviso that if Q 3 is —C(R 5 )— and m=0, then R 5 is not H;

R 6 is —H, halogen, —OH, —NH 2 , —C 1 -C 8 alkyl, or —O—(C 1 -C 8 alkyl);

R 7 and R 8 are independently —Y m (R d ) wherein R d is —H, —OH, halogen, —NH 2 , —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —CN, —NO 2 , —N 3 , —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —(C 1 -C 8 alkylene)-OH, —O-benzyl, —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -CI 2 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —CH 2 O(CH 2 ) p OR 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —C(O)R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 ;

R 9 , R 10 , R 11 , R 12 , and R 13 are independently —Y m (R e ) wherein R e is —H, halogen, —NH 2 , C 1 -C 8 alkyl, —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(C 2 -C 5 alkenyl), —N(C 2 -C 5 alkenyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —C(O)NH(C 1 -C 5 alkyl), —C(O)N(C 1 -C 5 alkyl) 2 , —NHC(O)(C 1 -C 5 alkyl), —NHC(═NH 2 + )NH 2 , —CN, —NO 2 , N 3 , -3- to 9-membered heterocycle, —OR 14 , —CH 2 O(CH 2 ) p OR 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —C(O)R 14 , —O—C(O)OR 14 , —C(O)C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 or R 11 and R 12 , together with the carbon atom to which each is attached, join to form a 5- to 9-membered ring; and

each R 14 is independently —H, —C 1 -C 8 alkyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —C 2 -C 9 alkenyl, or —C 2 -C 8 alkynyl;

each Y is independently —C 1 -C 8 alkylene-, —C 2 -C 8 alkenylene- or —C 2 -C 8 alkynylene-;

each m is independently 0 or 1;

each n is independently an integer ranging from 0 to 6; and

each p is independently an integer ranging from 1 to 6.

5 . The method of claim 4 , further comprising administering another therapeutic agent.

6 . The method of claim 4 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

7 . A method for treating or preventing anemia or thrombocytopenia, comprising administering to a subject in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound having the formula:

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 7 , further comprising administering another therapeutic agent.

9 . The method of claim 7 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

10 . A method for treating or preventing anemia or thrombocytopenia, comprising administering to a subject in need thereof an effective amount of a compound of Formula (Ic)

or a pharmaceutically acceptable salt thereof, wherein:

Q 2 is —C(R 3 )— or —N—;

Q 3 is —C(R 5 )— or —N—;

R 1 is —Y m (R a ), wherein —R a is —H, —OH, —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —OS(O) 2 OH, —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , or —NR 14 C(S)N(R 14 ) 2 ;

R 2 is —H, —C 1 -C 8 alkyl or —OH;

R 3 , R 4 , and R 5 are independently —Y m (R b ), wherein R b is —H, halogen, —NH 2 , —CN, —NO 2 , —SH, —N 3 , —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O(CH 2 ) n —C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 or R 3 and R 4 , or R 4 and R 5 together with the carbon atom to which each is attached, join to form a 5- to 9-meinbered ring;

R 6 is —H, halogen, —OH, —NH 2 , —C 1 -C 8 alkyl, or —O—(C 1 -C 8 alkyl);

R 7 is —Y m —(R c ), wherein —R c is —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —O-benzyl, —OH, —NH 2 , —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —CN, —NO 2 , —N 3 , —C 2 -C 8 alkynyl, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O(CH 2 ) n C(O)O(CH 2 ) n CH 3 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 ;

R 8 is —Y m (R d ), wherein —R d is —H, —OH, halogen, —NH 2 , —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —CN, —NO 2 , —N 3 , —C 1 -C 8 alkyl, —O—(C 1 -C 8 alkyl), —(C 1 -C 8 alkylene)-OH, —C 2 -C 8 alkenyl, —C 2 -C 8 alkynyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 ;

R 10 , R 11 , R 12 , and R 13 are independently —Y m (R e ), wherein —R e is —H, halogen, —NH 2 , C 1 -C 8 alkyl, —NH(C 1 -C 5 alkyl), —N(C 1 -C 5 alkyl) 2 , —NH(phenyl), —N(phenyl) 2 , —NH(naphthyl), —N(naphthyl) 2 , —C(O)NH(C 1 -C 5 alkyl), —C(O)N(C 1-5 -C 5 alkyl) 2 , —NHC(O)(C 1 -C 5 alkyl), —NHC(═NH 2 + )NH 2 , —CN, —NO 2 , N 3 , -3- to 9-membered heterocycle, —OR 14 , —O(CH 2 ) p OR 14 , —C(O)R 14 , —O—C(O)R 14 , —C(O)(CH 2 ) n —R 14 , —O—C(O)OR 14 , —O—C(O)NHR 14 , —O—C(O)N(R 14 ) 2 , —C(O)N(R 14 ) 2 , —C(O)OR 14 , —C(O)NHR 14 , —S—R 14 , —SOR 14 , —S(O) 2 R 14 , —NHC(O)R 14 , —NHSR 14 , —NHSOR 14 , —NHS(O) 2 R 14 , —O—C(S)R 14 , —O—C(S)OR 14 , —O—C(S)NHR 14 , —O—C(S)N(R 14 ) 2 , —C(S)OR 14 , —C(S)NHR 14 , —C(S)N(R 14 ) 2 , —NHC(S)R 14 , —NR 14 C(S)R 14 , —NHC(S)NHR 14 , —NHC(S)N(R 14 ) 2 , —NR 14 C(S)NHR 14 , —NR 14 C(S)N(R 14 ) 2 ; or R 11 and R 12 together with the carbon atom to which each is attached, join to form a 5- to 9-membered ring;

each R 14 is independently —H, —C 1 -C 8 alkyl, —C 3 -C 12 cycloalkyl, -phenyl, -naphthyl, -3- to 9-membered heterocycle, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl;

each Y is independently —C 1 -C 8 alkylene-, —C 2 -C 8 alkenylene- or —C 2 -C 8 alkynylene-;

each m is independently 0 or 1;

each n is independently an integer ranging from 0 to 6; and

each p is independently an integer ranging from 1 to 6.

11 . The method of claim 10 , further comprising administering another therapeutic agent.

12 . The method of claim 10 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

13 . The method of claim 1 , wherein the preventing is in a subject having a heightened risk of developing anemia or thrombocytopenia.

14 . The method of claim 13 , further comprising administering another therapeutic agent.

15 . The method of claim 13 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

16 . The method of claim 4 , wherein the preventing is in a subject having a heightened risk of developing anemia or thrombocytopenia.

17 . The method of claim 16 , further comprising administering another therapeutic agent.

18 . The method of claim 16 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

19 . The method of claim 7 , wherein the preventing is in a subject having a heightened risk of developing anemia or thrombocytopenia.

20 . The method of claim 19 , further comprising administering another therapeutic agent.

21 . The method of claim 19 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.

22 . The method of claim 10 , wherein the preventing is in a subject having a heightened risk of developing anemia or thrombocytopenia.

23 . The method of claim 22 , further comprising administering another therapeutic agent.

24 . The method of claim 22 , wherein the pharmaceutically acceptable salt is a tartrate salt or a mesylate salt.